In the world of clinical research, no principle is more important—or more sacred—than Informed Consent. It is the ethical and legal bedrock upon which all human research is built. For a Clinical Research Coordinator (CRC), it’s crucial to understand that informed consent is not merely a document to be signed; it is a comprehensive, open educational process designed to ensure that a person's decision to participate in a study is fully voluntary, intentional, and based on a clear understanding of all the relevant facts.
Protecting Autonomy and Human Rights
The core goal of the informed consent process is to respect and protect a person's autonomy—their right to make their own decisions about their body and their health. To safeguard this, global regulations like the ICH Good Clinical Practice (GCP) guidelines require a rigorous, standardized process.
The 8 Core Elements You Must Explain
These essential details must be included in the Informed Consent Form (ICF) and clearly explained in plain language by the research team:
- Purpose & Procedures: Why are we doing this study, what will it involve, and how long will it last?
- Risks & Discomforts: A clear, honest description of any reasonably foreseeable risks or side effects.
- Benefits: Potential benefits to the participant and science (note: benefits are never guaranteed).
- Alternatives: Disclosure of appropriate alternative treatments available outside the study.
- Confidentiality: How personal records and data will be protected and shared.
- Compensation & Injury: Information on financial compensation and medical treatment for study-related injury.
- Voluntary Participation: A statement that participation is 100% voluntary and participants can withdraw at any time.
The Critical Conversation: Avoiding Jargon
The face-to-face conversation between the researcher and the potential participant is the most important part of this process. The information must be conveyed in plain language, avoiding technical jargon. The CRC's role here is to be an educator and a listener.
Consent is Continuous, Not a One-Time Event
Finally, it's vital to remember that informed consent is an ongoing process. If any new information arises that could affect a participant's willingness to continue, the research team is obligated to share it. This ensures that consent is a continuous, informed agreement throughout the trial's duration.
Disclaimer: The information provided on this page is for educational and informational purposes only. It is intended to offer guidance and perspective on clinical research and does not constitute official professional or medical advice. We are not responsible for any decisions or actions taken based on this information. The CRC Toolkit is an independent educational resource. We are not affiliated with, endorsed by, or sponsored by the FDA, EMA, ICH, NIH, or any other regulatory authority or government agency.
Sources & Recommended Reading
CK
Written by
C. Kelley, CCRC, MBA
Certified Clinical Research Coordinator · 10+ Years in Clinical Research
A seasoned CRC and site management professional with over a decade of experience across Phase I–IV trials at academic medical centers and private research sites. Founder of The CRC Toolkit and an advocate for empowering site-level research staff with practical, accessible tools and education.
The Practical Consent Process: Step-by-Step for CRCs
Understanding the theory of informed consent is important, but knowing how to conduct the process in a real clinical setting — with real patients who are often anxious, in pain, or cognitively overwhelmed — is where the true skill lies. Here's how an experienced CRC approaches the consent process from start to finish.
Step 1: Set the Right Environment
Informed consent should never happen in a busy hallway, a crowded waiting room, or the last five minutes of a clinic appointment. Best practice is to schedule a dedicated consent visit where the patient has time to read, ask questions, and bring a family member or advocate if they choose. Privacy is not just courteous — it's a regulatory requirement.
Step 2: Assess Health Literacy — Without Making It Obvious
The National Institutes of Health estimates that nearly 90% of U.S. adults have health literacy challenges. Your ICF was written by lawyers and medical writers, and most participants will not be able to fully comprehend it without your help. Use the "teach-back" method: after explaining a concept, ask the participant to explain it back in their own words. This is not a test — it's a tool for ensuring genuine understanding.
Be alert to signs that the participant may have limitations: avoiding eye contact when asked about reading, nodding but answering questions incorrectly, or asking a family member to "just sign for them." These require additional steps, including potentially using certified translators, simplified consent materials (if approved), or involving social work.
Step 3: Walk Through the ICF Section by Section
Don't hand over a 30-page document and say "take your time." Structure the conversation. Walk through each major section of the informed consent form using plain language. The FDA and ICH GCP both require that participants be given "sufficient time and opportunity to decide." What constitutes sufficient time depends on the study complexity and participant circumstances — there's no universal minimum, but same-day consent for complex procedures is rarely appropriate.
⚠️ Common CRC Consent Mistakes That Lead to Protocol Deviations
- Consenting after study procedures have already begun — This is a serious GCP violation and potential FDA finding
- Using an expired consent form — Always verify the form version and IRB approval date before each consent
- Failing to re-consent when new safety information emerges — If a protocol amendment adds new risks, existing participants must re-consent
- Not documenting who was present — The consent note should include the date, time, who conducted consent, who was present, and any questions asked
- Applying pressure or time urgency — Even implicit pressure ("We need to start next week") can invalidate consent voluntariness
Re-Consent: When and Why It's Required
One of the most frequently misunderstood aspects of informed consent is re-consent. Many coordinators believe that once a participant signs, the consent process is complete. In fact, consent is an ongoing process, and specific circumstances trigger a mandatory re-consent regardless of when the original signature was obtained.
Re-consent is required when:
- A protocol amendment changes study procedures, visit schedules, or participant burden
- New safety information becomes available that could affect a participant's willingness to continue (e.g., a new adverse event identified in the study population)
- The informed consent form is updated by the sponsor or required by the IRB
- A participant's comprehension or decision-making capacity comes into question
- The participant requests to review the consent again
Failing to re-consent when required is one of the most common FDA inspection findings at clinical research sites. Develop a system for tracking which participants are on which version of the ICF and who needs re-consent following each protocol amendment.
Special Populations: Heightened Protections
Certain populations require additional safeguards beyond the standard informed consent process because of their potential vulnerability. The FDA and ICH GCP guidelines identify these groups specifically, and CRCs working with these populations must be especially diligent.
Children (Minors)
Require parental or guardian permission AND, for older children (typically 7+), the child's own assent. Assent forms are written at an age-appropriate reading level.
Cognitively Impaired Adults
Require a Legally Authorized Representative (LAR) to consent on their behalf. The study must explicitly allow LAR consent and the IRB must have approved this approach.
Prisoners
Subject to additional federal regulations (45 CFR Part 46 Subpart C) due to the coercive nature of their environment. Most trials avoid prisoner enrollment unless the research directly benefits prisoners as a class.
Non-English Speakers
Must receive consent in their primary language, using a translated ICF approved by the IRB. A certified interpreter (not a family member) must be used. The "short form" consent process has specific documentation requirements.
Documentation: What a Complete Consent Record Looks Like
The signed ICF is just one part of the consent documentation package. A complete, audit-ready consent record should include:
- The signed and dated ICF (correct version, signed before any study procedures)
- A source document note (in the medical chart or study file) documenting: date and time of consent, who conducted the consent discussion, who was present, any questions asked by the participant, and the participant's demonstrated understanding
- A copy provided to the participant (required by GCP)
- If re-consent occurred: both the original and updated forms retained, with documentation of why re-consent was needed
- If a translator or LAR was used: documentation of their role and credentials
During FDA inspections and sponsor monitoring visits, the consent documentation is among the first items reviewed. A clean, complete consent file is one of the hallmarks of a high-performing research site.